brotizolam

Brotizolam is a highly potent, short-acting thienotriazolodiazepine derivative and benzodiazepine analog with sedative-hypnotic properties. It is primarily indicated for the short-term treatment (2–4 weeks) of severe or debilitating insomnia, including difficulty falling asleep and frequent awakenings. Brotizolam acts as a positive allosteric modulator at the benzodiazepine site of the Gamma aminobutyric acid type A receptor (GABA-A receptor), enhancing GABAergic neurotransmission to produce its hypnotic, anxiolytic, anticonvulsant, muscle relaxant, and sedative effects. Its typical dose ranges from 0.125 to 0.25 mg with an average elimination half-life of about 4–5 hours[1][2][3][6]. Brotizolam is not approved in the US or UK but is marketed in several European countries and Japan.

Brand names

LendorminLendormLindorminSintonalMederantil

Other names

brotizolam